Silence Therapeutics plc Stock-Based Compensation
Silence Therapeutics plc (SLNCF) reported Stock-Based Compensation of $3.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Silence Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.31M, a 37.27% decline year-over-year.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.45M, a 30.88% decline year-over-year.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was -$86.00K, a 102.16% decline year-over-year.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.54M, a 37.67% decline year-over-year.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for fiscal 2025 was $8.07M, a 50.49% decline from fiscal 2024.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for fiscal 2024 was $16.31M, a 0.20% increase from fiscal 2023.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for fiscal 2023 was $16.27M, a 28.28% increase from fiscal 2022.
- Silence Therapeutics plc share-based payment arrangement, noncash expense for fiscal 2022 was $12.69M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.75M 10-Q · filed 2026-08-10 | $3.67M derived: sum of 3 quarters · filed 2026-08-10 | $6.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.45M 10-Q · filed 2026-05-07 | $2.36M derived: sum of 2 quarters · filed 2026-05-07 | $4.90M derived: sum of 3 quarters · filed 2026-05-07 | $6.98M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.45M derived: sum of 2 quarters · filed 2026-03-05 | $4.53M derived: sum of 3 quarters · filed 2026-08-10 | $8.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.62M derived: sum of 2 quarters · filed 2026-08-10 | $8.16M 10-Q · filed 2025-11-06 | $12.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.63M 10-Q · filed 2026-08-10 | $9.61M derived: sum of 3 quarters · filed 2026-08-10 | $13.67M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $3.54M 10-Q · filed 2026-05-07 | $7.52M derived: sum of 2 quarters · filed 2026-05-07 | $11.59M derived: sum of 3 quarters · filed 2026-05-07 | $15.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $8.05M derived: sum of 2 quarters · filed 2026-03-05 | $12.19M derived: sum of 3 quarters · filed 2026-03-05 | $16.31M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.21M derived: sum of 2 quarters · filed 2025-11-06 | $12.33M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.26M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $4.12M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $16.27M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $12.69M 10-K · filed 2025-02-27 |